enVVeno Medical (NASDAQ:NVNO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of enVVeno Medical (NASDAQ:NVNO) to a hold rating in a report released on Saturday morning,Wall Street Zen reports.

Several other brokerages also recently issued reports on NVNO. Zacks Research upgraded enVVeno Medical to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of enVVeno Medical in a research note on Friday, September 25th. Finally, LADENBURG THALM/SH SH upgraded enVVeno Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, enVVeno Medical has a consensus rating of “Hold”.

enVVeno Medical Trading Up 0.2%

NASDAQ:NVNO opened at $6.66 on Friday. The firm has a 50-day moving average price of $9.29 and a two-hundred day moving average price of $10.43. enVVeno Medical has a twelve month low of $6.55 and a twelve month high of $26.25. The company has a market capitalization of $4.60 million, a P/E ratio of -0.34 and a beta of 1.29.

enVVeno Medical (NASDAQ:NVNO) last announced its earnings results on Thursday, July 30th. The company reported ($5.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.69) by ($0.68). On average, equities research analysts predict that enVVeno Medical will post -16.19 earnings per share for the current year.

About enVVeno Medical

enVVeno Medical Corporation (NASDAQ: NVNO) is a medical device company focused on developing bioprosthetic solutions for vascular and cardiovascular diseases. The company’s technologies are designed to address conditions for which existing medical and surgical treatments may be limited or ineffective.

Its lead product candidate is the VenoValve, an investigational surgically implanted tissue-based valve intended to treat chronic deep venous insufficiency, including symptoms associated with post-thrombotic syndrome.